Skip to content Skip to navigation

Recent News

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has signed an agreement enabling multiple academic laboratories at Stanford University to access Twist Bioscience’s innovative antibody...
–  Total of $195 million raised to date to support expansion and clinical advancement of Graphite Bio pipeline of targeted gene integration therapies with curative potential –  The financing, led by RA Capital Management and Rock Springs Capital, included participation by other prominent new and...
Since its founding 50 years ago, only three executive directors have helmed Stanford’s tech transfer office. They sit down to talk leadership, “secret sauces,” and mission.
Jan 8 2021 | Endpoints News
Investors like to see big plans, and Kevin Judice has plenty. The DiCE Molecules CEO is plotting a clinical trial launch for the biotech’s lead small molecule for psoriasis and wants to double the staff in the next year and a half. On Friday, those big plans landed him an $80 million Series C round...
Dec 14 2020 | BUSINESS WIRE
- IND clearance for Phase 1/2 trial establishes Graphite Bio as the first company advancing potentially curative sickle cell gene editing therapy to restore normal hemoglobin expression - GPH101 harnesses the power of CRISPR and natural DNA repair mechanisms to precisely insert the correct DNA...

Pages